Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function
- Status
- CompletedResults none
- Why it is watched
- non-weight indication: kidney, endocrine
- Who it enrolls
- age 18 Years to 60 Years; male; healthy volunteers accepted; no BMI minimum stated; conditions: Healthy Volunteer Study; HPA; Cortisol Deficiency; Adrenal Insufficiency
- Interventions
- semaglutide; Placebo
- Conditions
- Healthy Volunteer Study; HPA; Cortisol Deficiency; Adrenal Insufficiency
- Phase and size
- NA · 22 participants
- Dates
- Start 2025-01-16
Primary completion 2025-10-31 - Sponsor
- University Hospital, Basel, Switzerland (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Change in serum cortisol after Rybelsus vs. Placebowithin 210 minutes after the intake of the study drug
02Eligibility
Who can take part
Inclusion Criteria: * Healthy male volunteers aged 18-60 years * BMI 18.5-30 kg/m2 * No regular medication Exclusion Criteria: * participation in a trial with investigational drugs within 30 days * vigorous physical exercise within 24 hours before the study participation * alcohol intake within 24 hours before the study participation * a history of intake of glucocorticoids or GLP-1 RA within the last 8 weeks. * Known allergy towards GLP-1 RA
03Change log
Registry changes
No changes recorded since the trial was added.